DE69802679D1 - Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen - Google Patents

Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen

Info

Publication number
DE69802679D1
DE69802679D1 DE69802679T DE69802679T DE69802679D1 DE 69802679 D1 DE69802679 D1 DE 69802679D1 DE 69802679 T DE69802679 T DE 69802679T DE 69802679 T DE69802679 T DE 69802679T DE 69802679 D1 DE69802679 D1 DE 69802679D1
Authority
DE
Germany
Prior art keywords
triazolo
treatment
disorders
cerbrovascular
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69802679T
Other languages
German (de)
English (en)
Inventor
Ennio Ongini
Marina Adami
Rosalia Bertorelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Italia SRL
Original Assignee
Schering Plough SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough SpA filed Critical Schering Plough SpA
Application granted granted Critical
Publication of DE69802679D1 publication Critical patent/DE69802679D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69802679T 1997-05-21 1998-05-14 Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen Expired - Lifetime DE69802679D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI001190A IT1291372B1 (it) 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
PCT/EP1998/002852 WO1998052568A1 (en) 1997-05-21 1998-05-14 THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES

Publications (1)

Publication Number Publication Date
DE69802679D1 true DE69802679D1 (de) 2002-01-10

Family

ID=11377184

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69802679T Expired - Lifetime DE69802679D1 (de) 1997-05-21 1998-05-14 Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen

Country Status (9)

Country Link
EP (1) EP0983068B1 (enExample)
JP (1) JP2002502370A (enExample)
CN (1) CN1255854A (enExample)
AT (1) ATE209492T1 (enExample)
AU (1) AU740475B2 (enExample)
CA (1) CA2289847A1 (enExample)
DE (1) DE69802679D1 (enExample)
IT (1) IT1291372B1 (enExample)
WO (1) WO1998052568A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1283839E (pt) 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
EP1575916B1 (en) 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
EP1430898A4 (en) * 2001-09-28 2005-11-02 Kyowa Hakko Kogyo Kk Receptor antagonist
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
CA2468658C (en) 2001-11-30 2009-04-14 Schering Corporation [1,2,4]-triazole bicyclic adenosine a2a receptor antagonists
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
AU2002346503A1 (en) 2001-11-30 2003-06-17 Schering Corporation Adenosine A2a receptor antagonists
EP1622912B1 (en) 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
ATE461932T1 (de) 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
AR057817A1 (es) 2005-09-19 2007-12-19 Schering Corp Antagonistas del receptor a2a de 2-heteroaril-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidin adenosina. composiciones farmaceuticas
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
ES2588238T3 (es) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
EP2939676A1 (en) 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
US20110190324A1 (en) * 2008-07-16 2011-08-04 Edward Leung Methods of treating atherosclerosis
BRPI0922700A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
EA201170769A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
PE20110922A1 (es) 2008-12-06 2012-01-22 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
AU2009322903A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
EP2434895A4 (en) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
ES2717688T3 (es) 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
AU2015350315B2 (en) 2014-11-18 2020-06-25 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
WO2016090382A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
WO2016126570A1 (en) 2015-02-06 2016-08-11 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
EP3307067B1 (en) 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
US12410175B2 (en) 2019-09-03 2025-09-09 Intra-Cellular Therapies, Inc. Compounds
CN111072676B (zh) * 2019-12-12 2021-07-16 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Also Published As

Publication number Publication date
ITMI971190A0 (enExample) 1997-05-21
AU740475B2 (en) 2001-11-08
IT1291372B1 (it) 1999-01-07
WO1998052568A1 (en) 1998-11-26
ITMI971190A1 (it) 1998-11-21
EP0983068B1 (en) 2001-11-28
CA2289847A1 (en) 1998-11-26
ATE209492T1 (de) 2001-12-15
JP2002502370A (ja) 2002-01-22
AU7654698A (en) 1998-12-11
EP0983068A1 (en) 2000-03-08
CN1255854A (zh) 2000-06-07

Similar Documents

Publication Publication Date Title
ATE209492T1 (de) Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen
TW200500344A (en) Novel compounds
SE9701398D0 (sv) Novel compounds
MX9807073A (es) Pirmido[5,4-d]pirimidinas, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparacion.
GB0329214D0 (en) Novel compounds
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
HU896762D0 (en) Process for preparation of pyrimidine-derivatives and for manufacturing of pharmaceutical compositions containing these compounds
FI904204A0 (fi) Foerfarande foer framstaellning av cykliska aminosyraderivat och mellanprodukter.
AU7575987A (en) N-phosphonylmethoxyalkyl pyrimidines and purines and therapeutic application thereof
HUT70505A (en) Pyrrolo[2,3-d]pyrimidine derivatives, pharmaceutical compositions containing them and process for preparing them
MX9701662A (es) Pirimido [5,4-d]pirimidinas, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparacion.
TW200503710A (en) Novel compounds
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
IL188184A0 (en) Pyrazolo [3,4-d] azepine derivatives as histamine h3 antagonists
SE9904129D0 (sv) Novel compounds
MY131024A (en) Immunostimulating 6-aryl-5, 6-dihydroimidazo [2,1-b] thiazole derivatives.
DE69320349D1 (de) Verwendung von guanosin zur herstellung von arzneimitteln zur behandlung von zerebralen funktionsstörungen
GR3034354T3 (en) IMIDAZO 1,2-a]QUINOXALIN-4-AMINES ACTIVE AS ADENOSINE ANTAGONISTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
BG102080A (en) Amino acid derivatives of substituted quinoxalin 2,3-dion derivatives such as glutamate receptor antagonists
DE69927251D1 (de) Verfahren zur herstellung von purinderivaten und dessen zwischenprodukte
PL376368A1 (en) 4-aminopiperidine derivatives, processes for their preparation and their use as medicaments
TWI245756B (en) Improved process for the preparation of 1,3-substituted indenes
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
ATE44743T1 (de) 4-oxo-pyrido(2,3>pyrimidin-derivate, verfahren zur deren herstellung und diese ethaltende arzneimittel.
HU9503099D0 (en) New piperazinyl-alkylthio-pyrimidine derivatives, pharmaceutical compositions containing them, and process for producing the active components

Legal Events

Date Code Title Description
8332 No legal effect for de